empagliflozin-话题@MedSci - 梅斯（MedSci）

#empagliflozin#

14篇内容 | 1244人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1954279, encodeId=e4e919542e9a1, content=<a href='/topic/show?id=ce586e31e6' target=_blank style='color:#2F92EE;'>#empagliflozin#</a>, objectTitle=EUR HEART J-CARD PHA：联合应用empagliflozin和linagliptin改善2型糖尿病患者的血压和血管功能, objectType=article, longId=205311, objectId=ecbc20531142, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ecbc20531142, replyNumber=0, likeNumber=100, createdTime=2021-12-18, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ecbc20531142, moduleTitle=EUR HEART J-CARD PHA：联合应用empagliflozin和linagliptin改善2型糖尿病患者的血压和血管功能, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=ecbc20531142)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954278, encodeId=75b419542e8d3, content=<a href='/topic/show?id=ce586e31e6' target=_blank style='color:#2F92EE;'>#empagliflozin#</a>, objectTitle=Diabetologia：Empagliflozin在兔糖尿病模型中调节肾交感神经和心率的压力反射？, objectType=article, longId=198247, objectId=9cba19824e8d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9cba19824e8d, replyNumber=0, likeNumber=88, createdTime=2021-07-13, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9cba19824e8d, moduleTitle=Diabetologia：Empagliflozin在兔糖尿病模型中调节肾交感神经和心率的压力反射？, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=9cba19824e8d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954277, encodeId=ff0519542e772, content=<a href='/topic/show?id=ce586e31e6' target=_blank style='color:#2F92EE;'>#empagliflozin#</a>, objectTitle=J Diabetes Investig：Empagliflozin治疗2型糖尿病和心血管疾病患者的效果, objectType=article, longId=195977, objectId=292c1959e7de, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=292c1959e7de, replyNumber=0, likeNumber=116, createdTime=2020-11-17, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=292c1959e7de, moduleTitle=J Diabetes Investig：Empagliflozin治疗2型糖尿病和心血管疾病患者的效果, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=292c1959e7de)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954276, encodeId=f41b19542e600, content=<a href='/topic/show?id=ce586e31e6' target=_blank style='color:#2F92EE;'>#empagliflozin#</a>, objectTitle=Boehringer Ingelheim和Lilly宣布empagliflozin作为1型糖尿病胰岛素的辅助治疗的全新结果, objectType=article, longId=141739, objectId=e257141e399a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e257141e399a, replyNumber=0, likeNumber=76, createdTime=2019-04-09, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e257141e399a, moduleTitle=Boehringer Ingelheim和Lilly宣布empagliflozin作为1型糖尿病胰岛素的辅助治疗的全新结果, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=e257141e399a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954274, encodeId=d93719542e4db, content=<a href='/topic/show?id=ce586e31e6' target=_blank style='color:#2F92EE;'>#empagliflozin#</a>, objectTitle=Lancet Diabetes Endo：empagliflozin可改善II糖尿病患者的尿蛋白水平, objectType=article, longId=103703, objectId=5757103e03c7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5757103e03c7, replyNumber=0, likeNumber=90, createdTime=2018-05-13, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5757103e03c7, moduleTitle=Lancet Diabetes Endo：empagliflozin可改善II糖尿病患者的尿蛋白水平, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=5757103e03c7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954275, encodeId=971919542e543, content=<a href='/topic/show?id=ce586e31e6' target=_blank style='color:#2F92EE;'>#empagliflozin#</a>, objectTitle=Redox Biol：empagliflozin改善原发性糖尿病并发症, objectType=article, longId=108726, objectId=577e108e26c4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=577e108e26c4, replyNumber=0, likeNumber=81, createdTime=2018-06-24, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=577e108e26c4, moduleTitle=Redox Biol：empagliflozin改善原发性糖尿病并发症, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=577e108e26c4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954273, encodeId=c19719542e339, content=<a href='/topic/show?id=ce586e31e6' target=_blank style='color:#2F92EE;'>#empagliflozin#</a>, objectTitle=Stroke：心血管疾病高风险的2型糖尿病患者Empagliflozin治疗与脑血管事件！, objectType=article, longId=95149, objectId=dcd4951496d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dcd4951496d, replyNumber=0, likeNumber=105, createdTime=2017-11-05, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dcd4951496d, moduleTitle=Stroke：心血管疾病高风险的2型糖尿病患者Empagliflozin治疗与脑血管事件！, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=dcd4951496d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954272, encodeId=5ceb19542e28a, content=<a href='/topic/show?id=ce586e31e6' target=_blank style='color:#2F92EE;'>#empagliflozin#</a>, objectTitle=NEJM：Empagliflozin可延缓2型糖尿病患者肾脏疾病的进展, objectType=article, longId=73108, objectId=19fde310878, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=19fde310878, replyNumber=0, likeNumber=87, createdTime=2016-09-15, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=19fde310878, moduleTitle=NEJM：Empagliflozin可延缓2型糖尿病患者肾脏疾病的进展, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=19fde310878)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954271, encodeId=4c1419542e1f6, content=<a href='/topic/show?id=ce586e31e6' target=_blank style='color:#2F92EE;'>#empagliflozin#</a>, objectTitle=NEJM：2型糖尿病患者接受empagliflozin治疗的心血管结果以及死亡率分析, objectType=article, longId=56314, objectId=12d25631402, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=12d25631402, replyNumber=0, likeNumber=77, createdTime=2016-04-23, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=12d25631402, moduleTitle=NEJM：2型糖尿病患者接受empagliflozin治疗的心血管结果以及死亡率分析, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=12d25631402)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954270, encodeId=3d5c19542e02d, content=<a href='/topic/show?id=ce586e31e6' target=_blank style='color:#2F92EE;'>#empagliflozin#</a>, objectTitle=FDA批准降糖药empagliflozin上市, objectType=article, longId=38679, objectId=a190386e966, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a190386e966, replyNumber=0, likeNumber=99, createdTime=2015-03-13, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a190386e966, moduleTitle=FDA批准降糖药empagliflozin上市, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=a190386e966)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954269, encodeId=7119195426973, content=<a href='/topic/show?id=ce586e31e6' target=_blank style='color:#2F92EE;'>#empagliflozin#</a>, objectTitle=Diabetes Care：SGLT-2抑制剂Empagliflozin添加胰岛素控制不佳的肥胖T2DM患者取得较好疗效（EMPA-REG MDI研究）, objectType=article, longId=36771, objectId=40bf36e716f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=40bf36e716f, replyNumber=0, likeNumber=0, createdTime=2015-03-30, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=40bf36e716f, moduleTitle=Diabetes Care：SGLT-2抑制剂Empagliflozin添加胰岛素控制不佳的肥胖T2DM患者取得较好疗效（EMPA-REG MDI研究）, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=40bf36e716f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954267, encodeId=ca14195426edf, content=<a href='/topic/show?id=ce586e31e6' target=_blank style='color:#2F92EE;'>#empagliflozin#</a>, objectTitle=勃林格-礼来糖尿病新药empagliflozin遭FDA拒绝, objectType=article, longId=31583, objectId=7ac63158356, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7ac63158356, replyNumber=0, likeNumber=77, createdTime=2014-11-15, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7ac63158356, moduleTitle=勃林格-礼来糖尿病新药empagliflozin遭FDA拒绝, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=7ac63158356)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954268, encodeId=ff03195426898, content=<a href='/topic/show?id=ce586e31e6' target=_blank style='color:#2F92EE;'>#empagliflozin#</a>, objectTitle=BI与礼来向FDA提交Empagliflozin/利格列汀复方药物上市申请, objectType=article, longId=33637, objectId=1d4c3363e7b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1d4c3363e7b, replyNumber=0, likeNumber=71, createdTime=2015-02-16, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1d4c3363e7b, moduleTitle=BI与礼来向FDA提交Empagliflozin/利格列汀复方药物上市申请, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=1d4c3363e7b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954266, encodeId=10751954266ad, content=<a href='/topic/show?id=ce586e31e6' target=_blank style='color:#2F92EE;'>#empagliflozin#</a>, objectTitle=Boehringer和Eli Lilly糖尿病新药empagliflozin三期研究数据公布, objectType=article, longId=20862, objectId=c4442086208, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c4442086208, replyNumber=0, likeNumber=89, createdTime=2014-06-15, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c4442086208, moduleTitle=Boehringer和Eli Lilly糖尿病新药empagliflozin三期研究数据公布, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=c4442086208)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

empagliflozin

2020-05-29

仁医06 (审核中...)

前往app查看评论内容

#empagliflozin#

EUR HEART J-CARD PHA：联合应用empagliflozin和linagliptin改善2型糖尿病患者的血压和血管功能

2021-12-18

仁医06 (审核中...)

前往app查看评论内容

#empagliflozin#

Diabetologia：Empagliflozin在兔糖尿病模型中调节肾交感神经和心率的压力反射？

2021-07-13

仁医06 (审核中...)

前往app查看评论内容

#empagliflozin#

J Diabetes Investig：Empagliflozin治疗2型糖尿病和心血管疾病患者的效果

2020-11-17

仁医06 (审核中...)

前往app查看评论内容

#empagliflozin#

Boehringer Ingelheim和Lilly宣布empagliflozin作为1型糖尿病胰岛素的辅助治疗的全新结果

2019-04-09

仁医06 (审核中...)

前往app查看评论内容

#empagliflozin#

Lancet Diabetes Endo：empagliflozin可改善II糖尿病患者的尿蛋白水平

2018-05-13

仁医06 (审核中...)

前往app查看评论内容

#empagliflozin#

Redox Biol：empagliflozin改善原发性糖尿病并发症

2018-06-24

仁医06 (审核中...)

前往app查看评论内容

#empagliflozin#

Stroke：心血管疾病高风险的2型糖尿病患者Empagliflozin治疗与脑血管事件！

2017-11-05

仁医06 (审核中...)

前往app查看评论内容

#empagliflozin#

NEJM：Empagliflozin可延缓2型糖尿病患者肾脏疾病的进展

2016-09-15

仁医06 (审核中...)

前往app查看评论内容

#empagliflozin#

NEJM：2型糖尿病患者接受empagliflozin治疗的心血管结果以及死亡率分析

2016-04-23

仁医06 (审核中...)

前往app查看评论内容

#empagliflozin#

FDA批准降糖药empagliflozin上市

2015-03-13

仁医06 (审核中...)

前往app查看评论内容

#empagliflozin#

Diabetes Care：SGLT-2抑制剂Empagliflozin添加胰岛素控制不佳的肥胖T2DM患者取得较好疗效（EMPA-REG MDI研究）

2015-03-30

仁医06 (审核中...)

前往app查看评论内容

#empagliflozin#

勃林格-礼来糖尿病新药empagliflozin遭FDA拒绝

2014-11-15

仁医06 (审核中...)

前往app查看评论内容

#empagliflozin#

BI与礼来向FDA提交Empagliflozin/利格列汀复方药物上市申请

2015-02-16

仁医06 (审核中...)

前往app查看评论内容

#empagliflozin#

Boehringer和Eli Lilly糖尿病新药empagliflozin三期研究数据公布

2014-06-15

科室
- - 订阅+
  - 更多科室
工具
服务